Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results News provided by Share this article Share this article - AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical studies show that pelareorep's synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors - Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021 - Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022